TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT01786707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose as per clinical management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin dose as per clinical management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dose as tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin dose as tolerated
Study: NCT01296581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82
Description: Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT00542074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hygienic information plus 62% ethyl alcohol in emollient gel
Description: The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hygienic information
Description: Couples received a brochure with information on control of STI and good hygienic practices.
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT06358456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No artificial tears
Description: Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No artificial tears
Description: Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
Study: NCT04638465

Intervention type: PROCEDURE
Intervention: Transoral robotic surgery
Description: Transoral resection with neck dissection

Intervention type: PROCEDURE
Intervention: Transoral robotic surgery
Description: Transoral resection with neck dissection

Intervention type: DRUG
Intervention: Cisplatin - Dose Level 1
Description: 6 Cycles of 40 mg/m2

Intervention type: DRUG
Intervention: Cisplatin - Dose Level 1
Description: 6 Cycles of 40 mg/m2

Intervention type: DRUG
Intervention: Cisplatin - Dose Level 2
Description: 7 Cycles of 40 mg/m2

Intervention type: RADIATION
Intervention: Dose Level 1
Description: 60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week

Intervention type: RADIATION
Intervention: Dose Level 2
Description: 70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
Study: NCT02126540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pantheris Atherectomy System
Description: Treatment device in primary cohort arm; OCT image guided directional atherectomy
Study: NCT03424837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCENT
Description: ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care
Study: NCT01250717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given by an IV infusion over 1 hour on day 2 of a three-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
Study: NCT04115098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT02612922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study: NCT00310817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, adjuvanted

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY polysaccharide vaccine
Study: NCT01151085

Intervention type: DRUG
Intervention: Voriconazole
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Study: NCT04274569

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaF vanish
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaF-TCP
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaF-CPP-ACP
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
Study: NCT04277104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop acoustic stimulation
Description: The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop acoustic stimulation
Description: The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop acoustic stimulation
Description: The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acoustic stimulation
Description: Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acoustic stimulation
Description: Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acoustic stimulation
Description: Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
Study: NCT02479594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: competence-feedback
Description: competence-feedback

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control group without competence-feedback
Study: NCT02538432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RQ-00000007
Description: RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RQ-00000007
Description: RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
Study: NCT04085354

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multi-Vitamin Tablets
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
Study: NCT00659867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes
Description: chromoscopy-guided endomicroscopy with targeted biopsies
Study: NCT04085354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine and folic acid.
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine and vitamin B12
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
Study: NCT02635503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transrectal specimen extraction
Description: After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Description: High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
Study: NCT02551874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin, Onglyza
Description: Tablets, Oral, 5mg , Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, Farxiga
Description: Tablets, Oral, 10mg , Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: 100 Units/ml solution for injection in a prefilled SoloStar pen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
Study: NCT02203305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
Study: NCT03015662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Therapy
Description: Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Therapy
Description: Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
Study: NCT02679924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid filler
Description: The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
Study: NCT01065662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given on days 1, 8, 15 and 22 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib
Description: Taken orally daily
Study: NCT04386798

Intervention type: OTHER
Group type: OTHER
Intervention: survey work
Description: Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
Study: NCT00659867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes
Description: Standard endoscopy with random and targeted biopsies
Study: NCT01493440

Intervention type: DRUG
Group type: OTHER
Intervention: atosiban
Description: Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Study: NCT01491802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA/LABA
Description: GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA/LABA
Description: GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA
Description: GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
Study: NCT01140477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Accommodating Lens
Description: Toric accommodating lens implanted after cataract extraction
Study: NCT04466657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidation Therapy
Description: Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study: NCT03713112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weekly MDT deprescribing rounds for certain drugs
Description: * Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care
Study: NCT01342809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Follow up, consultations with general practitioner, written guidelines, supervision.
Study: NCT03851536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound Guided ET
Description: Use of TVUS to guide ET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal Ultrasound Guided ET
Description: Use of TAUS to guide ET
Study: NCT01409382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily brisk walking plus a carbohydrate-restricted diet
Description: Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
Study: NCT04166188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar erector spinae plane block
Description: Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.